Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Recruiting · NCT07080385 · Registry updated 2026-04-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Recruiting | Phase 2 / Phase 3 | 2026-04-22 | NCT07080385 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Calcilytix Therapeutics, Inc., a BridgeBio company | 4 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's National Medical Center | Washington D.C. | United States | 177 |
| Nemours Children's Health | Jacksonville | United States | 9 |
| Royal London Hospital | London | United Kingdom | 14 |
| Royal Manchester Children's Hospital | Manchester | United Kingdom | 32 |
| The Children's Hospital of Philadelphia | Philadelphia | United States | 62 |
| Yale University | New Haven | United States | 44 |